Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically confirmed follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed)~* Measurable disease (At least one tumor mass \> 1 cm in diameter)~* Low tumor burden:~  1. No individual masses larger than 6 cm in diameter~ 2. No more than three masses larger than 3 cm in diameter~ 3. No lymphoma-related symptoms~* The treating physician does not feel that treatment with chemotherapy is indicated~* ECOG performance status of 0-2~* Adequate bone marrow and end organ function:~  i. ANC≥1500/mm3, hemoglobin≥10 g/dL, platelet≥100/mm3 ii. CrCL≥50 mL/min by Cockcroff Gault calculation~Exclusion Criteria:~* Indication for treatment of lymphoma including large tumor burden or symptomatic disease~* Pregnancy or men whose female partners are pregnant~* Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)~* Significant or unstable cardiac disease~* Hemoglobinopathy (thalassemia or sickle cell disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ribavirin (Type: EXPERIMENTAL): Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).